Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept plus docetaxel versus docetaxel plus placebo in second-line treatment of advanced NSCLC
2007-000819-29Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Aflibercept + docetaxel with Docetaxel + placebo (2 arms). Primary endpoint: Overall survival. Started Jun 2007; status: completed.
02
Drugs
aflibercept
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-000819-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000819-29.